Alignment Healthcare (ALHC) CEO files insider sale of 180,000 common shares

Rhea-AI Filing Summary

Alignment Healthcare, Inc. disclosed that Chief Executive Officer and director John E. Kao sold 180,000 shares of common stock on 12/10/2025. The sale was reported at a weighted-average price of $19.0179 per share, with individual trades executed between $18.84 and $19.46 under a Rule 10b5-1 trading plan adopted on 03/12/2025.

Following this transaction, Kao beneficially owns 2,346,726 shares indirectly through the JEK Trust, for which he serves as trustee, and 2,839,942 shares directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAO JOHN E

(Last) (First) (Middle)

1100 W. TOWN & COUNTRY RD., SUITE 1600

(Street)

ORANGE CA 92868

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/10/2025		S(1)		180,000	D	$19.0179(2)	2,346,726	I	See Footnote(3)
Common Stock								2,839,942	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Date of Rule 10b5-1 plan adoption: 03/12/2025

2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $18.84 to $19.46. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

3. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for John E. Kao	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Alignment Healthcare (ALHC) report?

Alignment Healthcare reported that Chief Executive Officer and director John E. Kao sold 180,000 shares of the companys common stock on 12/10/2025.

Who is John E. Kao in relation to Alignment Healthcare (ALHC)?

John E. Kao is both a Director and the Chief Executive Officer of Alignment Healthcare, Inc., making him a key executive and board member.

How many Alignment Healthcare shares did John E. Kao sell and at what price?

John E. Kao sold 180,000 shares of Alignment Healthcare common stock at a weighted-average price of $19.0179 per share, with individual sale prices ranging from $18.84 to $19.46.

Was the ALHC insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that the transaction was made under a Rule 10b5-1 trading plan, which was adopted on 03/12/2025.

How many Alignment Healthcare shares does John E. Kao own after the sale?

After the reported sale, John E. Kao beneficially owns 2,346,726 shares indirectly through the JEK Trust and 2,839,942 shares directly.

What is the JEK Trust mentioned in the Alignment Healthcare filing?

The filing explains that 2,346,726 shares are held by the JEK Trust, dated February 8, 2021, for which John E. Kao serves as trustee.